Surgalign Holdings (SRGA) Reports Smaller Q4 Loss

Surgalign Holdings (NASDAQ: SRGA) reported Q4 EPS of ($1.22), $0.60 better than the analyst estimate of ($1.82). Revenue for the quarter came in at $20.6 million versus the consensus estimate of $20.65 million.

For earnings history and earnings-related data on Surgalign Holdings (SRGA) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Eledon Pharmaceuticals, Inc. (ELDN) Misses Q2 EPS by 12c
• MapLight Therapeutics, Inc. (MPLT) Misses Q2 EPS by 33c